Literature DB >> 9172284

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.

J M Walenga1, W P Jeske, L Bara, M M Samama, J Fareed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9172284     DOI： 10.1016/s0049-3848(97)00042-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  13 in total

Review 1.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

2.  Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.

Authors:  Carolyne Lieu; Juan Shi; François Donat; Robert Van Horn; William Brian; John Newton; Leon Delbressine; Ria Vos
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins.

Authors:  Francis Paolucci; Marie-Christine Claviés; François Donat; José Necciari
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers.

Authors:  Céline Ollier; Richard A Faaij; Alix Santoni; Thierry Duvauchelle; Paul M M van Haard; Rik C Schoemaker; Adam F Cohen; Rik de Greef; Jacobus Burggraaf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis.

Authors:  Ravi S Keshari; Robert Silasi; Narcis I Popescu; Constantin Georgescu; Hala Chaaban; Cristina Lupu; Owen J T McCarty; Charles T Esmon; Florea Lupu
Journal:  J Thromb Haemost       Date:  2019-10-16       Impact factor: 5.824

Review 6.  Newer anticoagulants in 2009.

Authors:  Meyer Michel Samama; Grigoris T Gerotziafas
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

Review 7.  Fondaparinux sodium.

Authors:  Susan J Keam; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.

Authors:  Neil A Reynolds; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.

Authors:  Y Carmazzi; M Iorio; C Armani; S Cianchetti; F Raggi; T Neri; C Cordazzo; S Petrini; R Vanacore; F Bogazzi; P Paggiaro; A Celi
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

Review 10.  Fondaparinux: use in thromboprophylaxis of acute medical patients.

Authors:  Sohita Dhillon; Greg L Plosker
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.